PBI4050

Phase 2Small molecule

LLiminal BioSciences Ltd.

PBI4050 is one of 92 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

Abnormal Glucose ToleranceActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Metabolic SyndromePhase 2

Active, not recruiting

Abnormal Glucose TolerancePhase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

Precose

Bayer

Phase 3

1 2

Topamax

WWim Janssens

Phase 3

1 3

Glucophage

Boehringer Ingelheim

Phase 3

1 4

Kineret

SSwedish Orphan Biovitrum

Phase 3

1 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 6

Genotropin

Comparator: Statins

1 8

Rimonabant

Sanofi

Phase 3

—9

Berberine

XXijing Hospital of Digestive Diseases

Phase 3

2 10

Pioglitazone and Insulin

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolic Syndrome1 trial

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Completed·LLiminal BioSciences Ltd.·Phase 2·NCT02562573·24 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed·LLiminal BioSciences Ltd.·Phase 2·NCT02538536·41 enrolled

Abnormal Glucose Tolerance1 trial

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Terminated·LLiminal BioSciences Ltd.·Phase 2·NCT02955888·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PBI4050. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PBI4050 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PBI4050. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Liminal BioSciences Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLiminal BioSciences Ltd.

PBI4050

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolic Syndrome1 trial

Idiopathic Pulmonary Fibrosis1 trial

Abnormal Glucose Tolerance1 trial

References

Drug Info

Quick Facts

Related News